Royal Healthcare, a prominent medical institution in Singapore, has begun offering the FonesVisuas Test developed by NEC Corporation. This innovative blood test predicts disease risk, addressing the global rise in lifestyle-related diseases and dementia, as highlighted by the World Health Organisation (WHO). The test aims to enhance proactive health management by identifying potential health risks early.
Located in Singapore’s medical hub, Novena, Royal Healthcare is known for its personalised and high-quality health screening services. The institution combines cutting-edge medical expertise with hospitality, catering to both local and international patients. The introduction of the FonesVisuas Test aligns with the Organisation for Economic Co-operation and Development’s (OECD) findings, which identify cancer and cardiovascular diseases as leading causes of mortality worldwide.
NEC Corporation, listed on the Tokyo Stock Exchange, has developed the FonesVisuas Test to meet the growing demand for advanced predictive diagnostics. The test is part of Royal Healthcare’s commitment to providing efficient and convenient medical experiences. A spokesperson from NEC stated, “The FonesVisuas Test represents a significant advancement in disease risk prediction, offering patients a proactive approach to their health.”
As the healthcare landscape evolves, the integration of such predictive diagnostics is expected to play a crucial role in managing global health challenges. Royal Healthcare’s adoption of the FonesVisuas Test marks a step forward in enhancing patient care and disease prevention strategies.
